Lummis Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Lummis Asset Management's VRTX Position: Q2 2026 in Review
Lummis Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, buying an estimated $1.33K and bringing the position to 32 shares worth $15.9K. The position accounts for 0.01% of the portfolio, ranked #117.
Lummis Asset Management first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Lummis Asset Management held 32 shares of Vertex Pharmaceuticals worth $15.9K as of Q2 2026.
- Lummis Asset Management bought 3 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.33K.
- Vertex Pharmaceuticals made up 0.01% of Lummis Asset Management's portfolio in Q2 2026, its #117 holding.
- Lummis Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Lummis Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.